Table 3 Effectiveness In Head To Head Trials Comparing Biologic with Combination DMARD Strategies Assessed By Random Risk Ratio and Heterogeneity
From: Intensive therapy and remissions in rheumatoid arthritis: a systematic review
| Â | Trials | Random Risk Ratio (95% CI) | Heterogeneity |
|---|---|---|---|
All | 6 | 1.06 (0.93, 1.21) | I2 = 21% |
Early | 4 | 1.05 (0.88, 1.24) | I2 = 40% |
Established | 2 | 1.21 (0.88, 1.68) | I2 = 0% |
Established First 6 Months | 2 | 1.74 (1.14, 2.64) | I2 = 0% |